Revlimid (lenalidomide) is a brand-name oral capsule that’s prescribed for certain types of myeloma, lymphoma, and anemia. As with other drugs, Revlimid can cause side effects, such as skin rash and ...
Lenalidomide is a cornerstone therapy for multiple myeloma (MM) and other hematologic malignancies, but conventional oral dosing is limited by high peak plasma concentrations, rapid clearance, and ...
FDA approved Adcetris, Revlimid, and Rituxan for relapsed/refractory LBCL patients ineligible for auto-HSCT or CAR-T therapy, based on ECHELON-3 trial results. The combination therapy showed ...
Rituximab and lenalidomide combination therapy shows promise for relapsed/refractory indolent non-Hodgkin lymphoma, with high response and remission rates. The AUGMENT trial demonstrated favorable ...
The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with CAR-T cell therapies.As described in the patent application, STAR-LLD's ...
The potential of STAR-LLD to improve lenalidomide’s therapeutic index suggests an opportunity for use in combination with multi-specific (i.e.
TORONTO -- A quadruplet regimen elicited favorable outcomes in an older population of transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM), according to phase II trial data. The ...
PARAMUS, N.J., June 24, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results